Solna, Sweden — September 30, 2025 — Leads & Copy — Epigenica AB has launched the EpiFinder™ GenomePro product, utilizing its cutting-edge platform for advanced epigenomic research. The EpiFinder™ GenomePro enables researchers to explore histone post-translational modifications (hPTMs) and DNA methylation simultaneously with high throughput and cost-efficiency, while maintaining data quality.
The next-gen version of the EpiFinder™ Genome features optimized reagents and protocols for analyzing 24 samples in a single run. With EpiFinder™ GenomePro, researchers obtain data for 192 genome-wide Chromatin Immunoprecipitation Sequencing (ChIP-Seq) profiles for multiple hPTMs and DNA methylation from minimal sample volumes.
The reduced cost per sample is a key advantage, making large-scale studies more accessible. EpiFinder™ GenomePro has a flexible design, allowing researchers to choose their desired hPTMs with or without DNA methylation. The open-source data analysis pipeline ensures streamlined data analysis with transparency and reproducibility.
“With EpiFinder™ GenomePro, we’re setting a new standard in epigenomic research,” said Mohamad Takwa, CEO of Epigenica AB. EpiFinder™ GenomePro is poised to advance research across diverse therapeutic areas, helping decode the epigenetic mechanisms that drive disease onset, progression, and predict patient treatment response.
“The EpiFinder GenomePro kit offers an excellent method for labs with limited previous experience in ChIP-seq or similar methods to obtain high-quality ChIP-seq data – without significant time investment,” says Björn Reinius, Associate Professor at the Karolinska Institute. Epigenica AB is dedicated to empowering researchers with the tools to generate high throughput, multiplex, and quantifiable data in a cost-effective manner for broad epigenomic insights.
Discover more about how EpiFinder™ GenomePro can transform your research by visiting the Epigenica AB website.
Raffaella Giugliano
Product Marketing Manager
raffaella.giugliano@epigenica.se
Source: Epigenica AB
